[go: up one dir, main page]

EE200200579A - Akuutse ja kroonilise valu ja/või neuropaatilise valu ja migreenide ravimiseks kasutatav farmatseutiline kompositsioon - Google Patents

Akuutse ja kroonilise valu ja/või neuropaatilise valu ja migreenide ravimiseks kasutatav farmatseutiline kompositsioon

Info

Publication number
EE200200579A
EE200200579A EEP200200579A EEP200200579A EE200200579A EE 200200579 A EE200200579 A EE 200200579A EE P200200579 A EEP200200579 A EE P200200579A EE P200200579 A EEP200200579 A EE P200200579A EE 200200579 A EE200200579 A EE 200200579A
Authority
EE
Estonia
Prior art keywords
migraine
pain
pharmaceutical composition
treating acute
neuropathic pain
Prior art date
Application number
EEP200200579A
Other languages
English (en)
Estonian (et)
Inventor
Wadsworth Coe Jotham
Patrick Harrigan Edmund
Thomas O'neill Brian
Bradley Sands Steven
Jacob Watsky Eric
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200200579A publication Critical patent/EE200200579A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200200579A 2000-04-07 2001-03-16 Akuutse ja kroonilise valu ja/või neuropaatilise valu ja migreenide ravimiseks kasutatav farmatseutiline kompositsioon EE200200579A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19573800P 2000-04-07 2000-04-07
PCT/IB2001/000391 WO2001076576A2 (fr) 2000-04-07 2001-03-16 Composition pharmaceutique servant a traiter une douleur chronique aigue et/ou une douleur neurophatique ou des migraines

Publications (1)

Publication Number Publication Date
EE200200579A true EE200200579A (et) 2004-06-15

Family

ID=22722582

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200579A EE200200579A (et) 2000-04-07 2001-03-16 Akuutse ja kroonilise valu ja/või neuropaatilise valu ja migreenide ravimiseks kasutatav farmatseutiline kompositsioon

Country Status (35)

Country Link
US (2) US20010036943A1 (fr)
EP (1) EP1272218B1 (fr)
JP (1) JP2003530345A (fr)
KR (1) KR20030040201A (fr)
CN (1) CN1468111A (fr)
AP (1) AP2002002642A0 (fr)
AR (1) AR027773A1 (fr)
AT (1) ATE291438T1 (fr)
AU (1) AU3768001A (fr)
BG (1) BG107138A (fr)
BR (1) BR0109837A (fr)
CA (1) CA2405142A1 (fr)
CR (1) CR6767A (fr)
CZ (1) CZ20023214A3 (fr)
DE (1) DE60109589T2 (fr)
EA (1) EA004930B1 (fr)
EE (1) EE200200579A (fr)
ES (1) ES2236185T3 (fr)
GT (1) GT200100055A (fr)
HU (1) HUP0301822A3 (fr)
IL (1) IL152076A0 (fr)
IS (1) IS6560A (fr)
MA (1) MA26889A1 (fr)
MX (1) MXPA02009817A (fr)
NO (1) NO20024734D0 (fr)
OA (1) OA12241A (fr)
PA (1) PA8515001A1 (fr)
PE (1) PE20011307A1 (fr)
PL (1) PL365957A1 (fr)
SK (1) SK13952002A3 (fr)
SV (1) SV2002000377A (fr)
TN (1) TNSN01053A1 (fr)
WO (1) WO2001076576A2 (fr)
YU (1) YU74602A (fr)
ZA (1) ZA200207996B (fr)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU714980B2 (en) 1996-07-24 2000-01-13 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
CA2423449A1 (fr) * 2000-09-26 2002-04-04 The Brigham And Women's Hospital, Inc. Antidepresseurs tricycliques et leurs analogues comme anesthesiques et analgesiques locaux de longue duree
US7074961B2 (en) 2000-09-26 2006-07-11 The Brigham And Women's Hospital, Inc. Antidepressants and their analogues as long-acting local anesthetics and analgesics
CN1321107C (zh) * 2001-04-20 2007-06-13 辉瑞产品公司 1,3－取代的茚类和芳基稠合的氮杂多环化合物的制备方法
ES2357808T3 (es) * 2001-06-07 2011-04-29 Christine Dr. Sang Tratamiento del dolor neuropático con antagonistas del receptor de n-metil-d-aspartato (nmda).
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US20040138239A1 (en) * 2001-08-23 2004-07-15 Bruce Frome Compositions and methods for targeting cerebral circulation and treatment of headache
US6562816B2 (en) 2001-08-24 2003-05-13 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
US6911543B2 (en) 2001-10-02 2005-06-28 Pfizer Inc. Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
JP2005510523A (ja) 2001-11-09 2005-04-21 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー アザ二環式フェニル縮合複素環式化合物、及びα７ＮＡＣＨＲリガンドとしての当該化合物の使用
US20030170326A1 (en) * 2001-12-13 2003-09-11 Council Of Scientific And Industrial Research Bioavailability enchancing activity of Zingiber officinale Linn and its extracts/fractions thereof
PL371587A1 (en) * 2002-01-17 2005-06-27 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin receptors
WO2003066040A1 (fr) 2002-02-05 2003-08-14 Ajinomoto Co.,Inc. Compositions medicinales contenant une gabapentine ou une pregabaline et antagoniste a canal de calcium de type n
JP2005522445A (ja) * 2002-02-12 2005-07-28 サイプレス バイオサイエンス， インコーポレイテッド 注意欠陥過活動性障害（ａｄ／ｈｄ）の処置方法
MXPA04007936A (es) 2002-02-15 2004-11-26 Upjohn Co Compuestos de aril-sustituidos para el tratamiento de enfermedades.
JP2005523288A (ja) 2002-02-19 2005-08-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾病治療用の縮合した二環式−ｎ−架橋−複素環式芳香族カルボキサミド
AU2003217275A1 (en) 2002-02-19 2003-09-09 Pharmacia And Upjohn Company Azabicyclic compounds for the treatment of disease
CA2483093A1 (fr) * 2002-04-24 2003-11-06 Cypress Bioscience, Inc. Prevention et traitement de troubles somatiques fonctionnels, y-compris les troubles lies au stress
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
AU2003239455A1 (en) * 2002-05-14 2003-12-02 Ralph Ryback Method for treating dermatoses and tissue damage
MXPA04011206A (es) * 2002-05-15 2005-02-14 Abbott Lab Tratamiento de dolor neuropatico.
JP4615309B2 (ja) 2002-05-17 2011-01-19 オセラ・ホールディング・インコーポレイテッド 白内障および他の眼球疾患の進行の改善
CA2497780A1 (fr) * 2002-10-17 2004-04-29 Novartis Ag Composition pharmaceutique pour le traitement de la douleur comprenant de l'oxycarbazepine, ou certains de ses derives, et inhibiteurs de cox2
EP1578787B1 (fr) 2002-12-02 2012-11-14 Xenome Ltd Nouveaux peptides de chi-conotoxine (-ii)
US7851444B2 (en) 2002-12-02 2010-12-14 Xenome Ltd. χ-conotoxin peptides (-1)
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
ATE359075T1 (de) 2002-12-20 2007-05-15 Niconovum Ab Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose
AU2004216904B2 (en) * 2003-03-06 2009-12-24 Botulinum Toxin Research Associates, Inc. Treatment of sinusitis related chronic facial pain and headache with botulinum toxin
AU2004230915B2 (en) * 2003-04-08 2008-08-07 Algorx Pharmaceuticals, Inc. Preparation and purification of synthetic capsaicin
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
WO2004105690A2 (fr) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Traitement de douleurs chroniques au moyen de chimiotherapie ou de radiotherapie
WO2005000806A2 (fr) 2003-06-10 2005-01-06 Georgetown University Ligands pour les recepteurs de l'acetylcholine nicotinique, et procedes de production et d'utilisation de ces ligands
US20050004219A1 (en) * 2003-07-01 2005-01-06 Medtronic, Inc. Pump systems including injectable gabapentin compositions
US20050004221A1 (en) * 2003-07-01 2005-01-06 Medtronic, Inc. Intrathecal gabapentin compositions
US20050043406A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2005032556A1 (fr) 2003-10-02 2005-04-14 Elan Pharmaceuticals, Inc. Methode de soulagement de la douleur
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
US20050090549A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of pain
AU2004291082A1 (en) 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
HU230403B1 (hu) * 2003-12-19 2016-04-28 Pál Kocsis Nátrium csatorna blokkoló és szerotonin újrafelvétel gátló tartalmú gyógyszerkészítmény
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
US20060002989A1 (en) * 2004-06-10 2006-01-05 Ahmed Salah U Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
EP1807018A4 (fr) * 2004-10-21 2012-07-04 Univ Iowa Res Found Systeme d'administration in situ de medicaments a liberation controlee
WO2006053012A2 (fr) * 2004-11-10 2006-05-18 Trinity Laboratories, Inc. Nouvelles compositions pharmaceutiques destinees a traiter la douleur chronique acquise et la dysphorie associee
MX2007006253A (es) * 2004-11-24 2007-10-18 Anesiva Inc Formulacion de gel de capsaicinoide y usos para esta.
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
MX2007014613A (es) 2005-05-20 2008-04-02 Johnson & Johnson Procedimiento para la preparacion de derivados de sulfamida.
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
AU2007224584A1 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
JP2007308403A (ja) * 2006-05-17 2007-11-29 Kenji Yoshida 皮膚外用剤
EP2026790A2 (fr) 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Thérapie combinée pour le traitement de l'épilepsie et de troubles apparentés
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
EP2051735B1 (fr) * 2006-07-17 2012-08-29 Ramot, at Tel Aviv University Ltd. Conjugues comprenant un remède psychotropique ou un gaba agoniste et un acide organique et leur utilisation pour le traitement de douleurs et autre troubles du snc
JPWO2008020651A1 (ja) * 2006-08-17 2010-01-07 国立大学法人九州大学 Ｐ２ｘ４受容体アンタゴニスト
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US7645767B2 (en) * 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
US20080119820A1 (en) * 2006-09-20 2008-05-22 Phan Phillip C Methods for Delivering Volatile Anesthetics for Regional Anesthesia and/or Pain Relief
US20100048605A1 (en) * 2006-12-11 2010-02-25 University Of Kentucky Research Foundation Synergistic effects of combinations of nornicotine and opioids for the treatment of pain
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
AU2008299921B2 (en) 2007-09-13 2012-03-01 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
EP2381834A2 (fr) * 2008-01-31 2011-11-02 Fund for Medical Research Development of Infrastructure & Health Services Rambam Medical Center Procédé de prédiction d'efficacité d'analgésique
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
ES2604968T3 (es) * 2008-04-28 2017-03-10 Zogenix, Inc. Nuevas formulaciones para el tratamiento de la migraña
WO2010008776A2 (fr) 2008-06-23 2010-01-21 Janssen Pharmaceutica Nv Ensemble avec timbre à usage unique et capteur réutilisable pour utilisation dans les systèmes de localisation et de cartographie de dispositifs médicaux
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US20100184685A1 (en) * 2009-01-19 2010-07-22 Zavala Jr Gerardo Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein
US8846765B2 (en) 2010-06-15 2014-09-30 Gruenenthal Gmbh Pharmaceutical combination
WO2012038963A1 (fr) 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. Sel d'addition d'acide d'un conjugué nortriptyline-gaba et son procédé de préparation
KR101572336B1 (ko) 2010-12-22 2015-11-26 퍼듀 퍼머 엘피 케이싱된 탬퍼 저항성 제어 방출 투여 형태
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
MX2013009544A (es) * 2011-02-18 2013-09-26 Nestec Sa Metodos y composiciones para tratar, reducir o prevenir daño al sistema nervioso de animales.
ES2387973B1 (es) * 2011-03-18 2013-10-01 Dr Healthcare España, S. L. Composiciones tópicas que contienen diaminooxidasa para el tratamiento o la prevención de enfermedades asociadas a un nivel de histamina elevada que comportan un aumento del dolor.
US8580850B2 (en) 2011-08-11 2013-11-12 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use
WO2014028800A1 (fr) * 2012-08-16 2014-02-20 Janssen Pharmaceutica Nv Pyrazoles substitués comme bloqueurs de canal calcique de type n
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CA2919892C (fr) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Comprime extrude anti-abus a liberation immediate
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
EP3209282A4 (fr) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Forme galénique anti-abus de remplissage de liquide à libération prolongée
CN104758933A (zh) * 2014-10-29 2015-07-08 吴鑫欣 治疗神经卡压、神经瘤疼痛的药物和给药系统
CA3057304A1 (fr) * 2017-03-22 2018-09-27 Bonti, Inc. Neurotoxines de botulinum pour le traitement de lesions traumatiques
WO2018183320A1 (fr) * 2017-03-31 2018-10-04 Depco, Inc. Mastic thérapeutique à analgésiques et/ou révulsifs
CA3059435A1 (fr) * 2017-04-12 2018-10-18 Synergistic Therapeutics, Llc Lotion therapeutique contre la douleur neuropathique
EP4650374A2 (fr) * 2017-05-10 2025-11-19 Axsome Therapeutics, Inc. Compositions pharmaceutiques comprenant du méloxicam
KR101944113B1 (ko) 2017-09-28 2019-01-30 동의대학교 산학협력단 급성 안면통증 예방 및 개선용 조성물
KR102156627B1 (ko) 2018-12-20 2020-09-16 동의대학교 산학협력단 보스웰리아 추출물 및 산자나무 추출물을 포함하는 급성 안면통증 예방 및 개선용 조성물
KR102156438B1 (ko) 2018-12-20 2020-09-16 동의대학교 산학협력단 급성 안면통증 예방 및 개선용 조성물
CN115054601B (zh) * 2022-03-21 2024-04-26 中山大学附属第三医院 一种可注射的缓释镇痛复合物及其制备方法、应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE326468T1 (de) * 1996-10-30 2006-06-15 Pfizer Pyridon-kondensierte azabicyclische- oder cytisin-derivate, ihre herstellung und verwendung in der suchttherapie
EP0955301A3 (fr) * 1998-04-27 2001-04-18 Pfizer Products Inc. Dérivés de 7-aza-bicyclo[2.2.1]-heptane, leur préparation et utilisation sur la base d'affinité pour les recepteurs de l'acetylcholine nicotinique neuronaux
DK1076650T3 (da) * 1998-04-29 2004-05-24 Pfizer Prod Inc Arylfusionerede, azapolycykliske forbindelser
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

Also Published As

Publication number Publication date
EP1272218B1 (fr) 2005-03-23
WO2001076576A3 (fr) 2002-06-20
MA26889A1 (fr) 2004-12-20
CR6767A (es) 2004-06-09
DE60109589D1 (de) 2005-04-28
IS6560A (is) 2002-09-20
EP1272218A2 (fr) 2003-01-08
CN1468111A (zh) 2004-01-14
KR20030040201A (ko) 2003-05-22
BR0109837A (pt) 2003-01-21
CZ20023214A3 (cs) 2003-11-12
ATE291438T1 (de) 2005-04-15
WO2001076576A2 (fr) 2001-10-18
EA200200910A1 (ru) 2003-02-27
PA8515001A1 (es) 2002-02-21
SK13952002A3 (sk) 2003-12-02
NO20024734D0 (no) 2002-10-02
EA004930B1 (ru) 2004-10-28
PE20011307A1 (es) 2001-12-28
IL152076A0 (en) 2003-05-29
US20010036943A1 (en) 2001-11-01
AU3768001A (en) 2001-10-23
CA2405142A1 (fr) 2001-10-18
AP2002002642A0 (en) 2002-12-31
ES2236185T3 (es) 2005-07-16
BG107138A (en) 2003-05-30
SV2002000377A (es) 2002-07-03
GT200100055A (es) 2001-12-31
DE60109589T2 (de) 2005-09-01
HUP0301822A2 (hu) 2003-11-28
ZA200207996B (en) 2003-10-20
YU74602A (sh) 2006-05-25
TNSN01053A1 (fr) 2005-11-10
HUP0301822A3 (en) 2005-06-28
MXPA02009817A (es) 2003-03-27
AR027773A1 (es) 2003-04-09
JP2003530345A (ja) 2003-10-14
PL365957A1 (en) 2005-01-24
OA12241A (en) 2004-01-27
US20030133951A1 (en) 2003-07-17

Similar Documents

Publication Publication Date Title
EE200200579A (et) Akuutse ja kroonilise valu ja/või neuropaatilise valu ja migreenide ravimiseks kasutatav farmatseutiline kompositsioon
DE60132052D1 (de) Bohr- und Behandlungsflüssigkeiten
FI20002429L (fi) Päällepuhalluskuivatusyksikkö ja kuivatusosa
FI7569U1 (fi) Farmaseuttinen koostumus luun uudelleenmuovauksen häiriön hoitamiseksi tai estämiseksi
EE200200626A (et) Antraniilamiidid ja nende kasutamine ravimitena
EE200200571A (et) Hüdroksüfenüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks
EP1345331A4 (fr) Codeur et decodeur
EP1363761A4 (fr) Materiau et procede de traitement pour bois debite
EP1605301A4 (fr) Micro-capsule et application de celle-ci
EE200200511A (et) Hüdroksüfenüülpiperasinüülmetüülbensamiidi derivaadid valu raviks
EE05534B1 (et) IL-18 inhibiitorite kasutamine ravimi valmistamiseks kardiomopaatia raviks ja/v?i ennetamiseks
DE60116488D1 (de) Fadenliefervorrichtung und -verfahren
FI20002636L (fi) Menetelmä ja järjestelmä elektronisen sisällön jakelemiseksi
FI20001985A0 (fi) Laitteisto ja menetelmä palautuspullojen käsittelyssä
DE50112350D1 (de) Arzneimittel enthaltend aktiviertes antithrombin iii
DE10081194D2 (de) Darreichungsform zur Applikation in Körperöffnungen
EE200100281A (et) Analgeetiline ravimkoostis
NO20030593L (no) Fremgangsmater for behandling av cancer og smerten forbundet derved ved a anvende endotelinantagonister
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
FI20031588L (fi) Esikalanterointimenetelmä ja paperin käsittelylinja
EE200200705A (et) Süsteemid ja meetodid limaskesta ravimiseks
EE200200348A (et) Ravimkoostis kasutamiseks valu ravis
EE200200350A (et) Ühend ja meetod valu raviks
FI19992294L (fi) Järjestely ja menetelmä sanan pituuden rajoittamiseksi
FI20010851L (fi) Järjestely ja menetelmä selluloosapitoisen materiaalin syöttämiseksi